星空体育官方入口网站网址大全-登录入口官网

#RRMM#

2篇内容 | 674人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2204164, encodeId=4c03220416472, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【Blood Adv】首次对比CAR-T和双抗：治疗三重难治RRMM的回顾性研究, objectType=article, longId=825326, objectId=f186825326d2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240511/1715434220624_5579292.jpg, objectUrl=/article/show_article.do?id=f186825326d2, replyNumber=0, likeNumber=44, createdTime=2024-05-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f186825326d2, moduleTitle=【Blood Adv】首次对比CAR-T和双抗：治疗三重难治RRMM的回顾性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f186825326d2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200833, encodeId=b1902200833d1, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【Nat Commun】BCMA和CD19双特异性CAR-T治疗RRMM的中国I/II期研究, objectType=article, longId=823394, objectId=bf0882339437, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PAJM2K5.jpg, objectUrl=/article/show_article.do?id=bf0882339437, replyNumber=0, likeNumber=35, createdTime=2024-04-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bf0882339437, moduleTitle=【Nat Commun】BCMA和CD19双特异性CAR-T治疗RRMM的中国I/II期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bf0882339437)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193018, encodeId=64df2193018f0, content=<a href='/topic/show?id=e69f11185836' target=_blank style='color:#2F92EE;'>#BCMA CAR-T#</a> <a href='/topic/show?id=c717425931e' target=_blank style='color:#2F92EE;'>#复发难治性多发性骨髓瘤#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a> <a href='/topic/show?id=26651122455a' target=_blank style='color:#2F92EE;'>#MyCARe#</a>, objectTitle=【JCO】BCMA CAR-T治疗RRMM的MyCARe预后模型, objectType=article, longId=816973, objectId=b0f28169e3d2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=b0f28169e3d2, replyNumber=0, likeNumber=52, createdTime=2024-03-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b0f28169e3d2, moduleTitle=【JCO】BCMA CAR-T治疗RRMM的MyCARe预后模型, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b0f28169e3d2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192543, encodeId=170e2192543c2, content=<a href='/topic/show?id=e69f11185836' target=_blank style='color:#2F92EE;'>#BCMA CAR-T#</a> <a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【Blood Adv】多发性骨髓瘤BCMA CAR-T复发后挽救治疗（含抗BCMA再治疗）的结局, objectType=article, longId=816721, objectId=27d2816e211a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-at-work-PGMH47J.jpg, objectUrl=/article/show_article.do?id=27d2816e211a, replyNumber=0, likeNumber=43, createdTime=2024-03-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=27d2816e211a, moduleTitle=【Blood Adv】多发性骨髓瘤BCMA CAR-T复发后挽救治疗（含抗BCMA再治疗）的结局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=27d2816e211a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177467, encodeId=b3f921e7467fc, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, objectType=article, longId=806561, objectId=31fe806561d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=31fe806561d8, replyNumber=0, likeNumber=61, createdTime=2023-12-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31fe806561d8, moduleTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=31fe806561d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2126335, encodeId=bd29212633551, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=6dbf10589ea2' target=_blank style='color:#2F92EE;'>#CD3/BCMA双抗#</a><a href='/topic/show?id=8ecd10589883' target=_blank style='color:#2F92EE;'>#Elranatamab#</a>治疗<a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a><a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布, objectType=article, longId=751741, objectId=209ee51741ba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/bea5c122810c404a8ba7de429c8571e3.jpg, objectUrl=/article/show_article.do?id=209ee51741ba, replyNumber=0, likeNumber=119, createdTime=2023-04-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=209ee51741ba, moduleTitle=ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=209ee51741ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2106183, encodeId=9205210618383, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a> <a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>对<a href='/topic/show?id=c0f04250423' target=_blank style='color:#2F92EE;'>#复发/难治性多发性骨髓瘤#</a> (<a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>) 的ORR高达100%，<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=ASH 2022：BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%, objectType=article, longId=751775, objectId=7a43e517755a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/a9bcb1349b95450e89ed095619943365.jpg, objectUrl=/article/show_article.do?id=7a43e517755a, replyNumber=0, likeNumber=0, createdTime=2022-12-15, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7a43e517755a, moduleTitle=ASH 2022：BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7a43e517755a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 侠胆医心

BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%，多发性骨髓瘤

2022-12-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #CAR-T# #RRMM#

【Blood Adv】首次对比CAR-T和双抗：治疗三重难治RRMM的回顾性研究

2024-05-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #CAR-T# #BCMA# #RRMM#

【Nat Commun】BCMA和CD19双特异性CAR-T治疗RRMM的中国I/II期研究

2024-04-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#BCMA CAR-T# #复发难治性多发性骨髓瘤# #RRMM# #MyCARe#

【JCO】BCMA CAR-T治疗RRMM的MyCARe预后模型

2024-03-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#BCMA CAR-T# #多发性骨髓瘤# #RRMM#

【Blood Adv】多发性骨髓瘤BCMA CAR-T复发后挽救治疗（含抗BCMA再治疗）的结局

2024-03-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松# #泊马度胺# #达雷妥尤单抗# #RRMM#

2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS

2023-12-27发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#辉瑞##CD3/BCMA双抗##Elranatamab#治疗#RRMM##多发性骨髓瘤#

ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布

2023-04-16发表于香港

侠胆医心 (审核中...)

前往app查看评论内容

#BCMA# #CAR-T细胞治疗#对#复发/难治性多发性骨髓瘤# (#RRMM#) 的ORR高达100%，#多发性骨髓瘤#

ASH 2022：BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%

2022-12-15发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务